Isoniazid: Clinical Trials

30 trials of Isoniazid, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 8 unknown, 3 active not recruiting, 2 terminated. 30 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 430Completed 15, Unknown 8, Active not recruiting 3, Terminated 2, Recruiting 1, Withdrawn 1

Follow Isoniazid: new trials by email Literature Review of Isoniazid trials Research Report on Isoniazid

Trials (filtered) newest first · largest first

All 30 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease
Rifampicin plus Isoniazid, Rifapentine plus Isoniazid, Rifampicin alone - Latent Tuberculosis, Kidney Failure
Phase 4UnknownMiguel Santín2252024-04-202024-03-15
Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
Daily rifapentine and isoniazid for 4 weeks, Weekly rifapentine and isoniazid for 12 weeks - HIV Seropositivity, Tuberculosis
Phase 4Active not recruitingThe Aurum Institute NPC10002023-07-192025-12-12
Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis
BaiDiZiYin Pill, ShenQiYiFei Pill, Anti tuberculosis chemotherapy - Adjuvant, Treatment
Phase 4RecruitingBeijing Chest Hospital2922023-05-292024-05-08
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
1 month Rifapentine, Isoniazid and Vitamin B6 - Latent Tuberculosis, End Stage Renal Disease
Phase 4Active not recruitingRutgers, The State University of New Jersey252022-07-012026-01-21
Ultra Curto (Ultra Short) TB Prevention Therapy
Rifapentine 600 mg and INH 300 mg, Rifapentine 900 mg and INH 900 mg - Tuberculosis
Phase 4CompletedJohns Hopkins University5312022-03-242025-06-19
Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
Rifampicin 300 Mg Oral Capsule, Isoniazid 300 Mg ORAL TABLET - Latent Tuberculosis, Diabetes Mellitus, Type 2
Phase 4CompletedHerlev and Gentofte Hospital322021-04-152023-05-16
Vaginal Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy in Primarily Infertile Patients
INH, Placebo - Infertility, Female
Phase 4CompletedAswan University Hospital1502020-09-012021-09-29
Vaginal Isonicotinic Acid Hydrazide (INH) Administration Prior to T380A Intrauterine Device Insertion
INH, Placebo Comparator - IUCD Complication
Phase 4CompletedAswan University Hospital2202020-09-012021-08-09
Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2 (TBL)
Isoniazid 300 mg Oral Tablet, Rifampin 600 mg Oral Tablet - Diabetes Mellitus, Tuberculin (Skin Test) Positive
Phase 4CompletedInstituto Nacional de Salud Publica, Mexico3962019-02-282019-04-26
Latent Tuberculosis in Type 2 Diabetes
Rifapentine and Isoniazid for 3 months, Isoniazid (INH) daily for 9 months - Latent Tuberculosis Infection
Phase 4Active not recruitingTaichung Veterans General Hospital5522018-04-182025-03-13
Treatment of Latent Tuberculosis in Socially Marginalised Citizens
Rifapentine, Isoniazid - Compliance, Patient
Phase 4TerminatedAarhus University Hospital222017-10-272023-10-12
Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT)
Isoniazid 300 Mg ORAL TABLET, Pyridoxine 25 Mg Oral Tablet - Tuberculosis, HIV/AIDS
Phase 4CompletedUniversity of California, San Francisco3022017-04-072023-10-19
Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis
Isoniazid, Rifampicin, Pyrazinamide - Tuberculosis, Pulmonary
Phase 4UnknownBeijing Chest Hospital39002016-08-012017-03-20
The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis
Isoniazid, Rifampicin, Ethambutol - Tuberculosis, Spinal
Phase 4UnknownBeijing Chest Hospital4002015-04-012015-06-23
Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3
Xpert MTB/RIF®, Determine TB LAM, Chest X-ray, ART (Atripla, Truvada, Efavirenz, Combivir), Rifampin, isoniazid, pyrazinamide, ethambutol - HIV-1 Infection
Phase 4CompletedANRS, Emerging Infectious Diseases10502014-09-012020-10-19
Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women
Isoniazid (INH), Placebo for isoniazid (INH) - HIV Infections, Tuberculosis
Phase 4CompletedNational Institute of Allergy and Infectious Diseases (NIAID)9562014-08-192021-11-05
Research on New Regimens for Retreatment Pulmonary Tuberculosis
Isoniazid Aminosalicylate Tablets, Streptomycin injectable - Reinfection Pulmonary Tuberculosis
Phase 4UnknownShanghai Pulmonary Hospital, Shanghai, China8642013-06-012015-01-06
Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes
Rifampicin, Isoniazid, Ethambutol, Pyrazinamide - AIDS With Tuberculosis
Phase 4UnknownMakerere University4002013-02-012015-04-13
Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis
Isoniazid 300Mg Tab, Isoniazid 300 MG - Latent Tuberculosis, Diabetes Mellitus
Phase 4WithdrawnInstituto Nacional de Salud Publica, Mexico2012-09-012018-04-17
REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
Atripla (r), Efavirenz, Truvada - HIV Infection
Phase 4CompletedAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections8512011-10-012024-10-15

Showing 20 of 30. Sign in to see all of them.

Conditions studied

Tuberculosis (18)  ·  Latent Tuberculosis (10)  ·  Acquired Immunodeficiency Syndrome (5)  ·  HIV Infections (5)  ·  Diabetes Mellitus (3)  ·  Tuberculosis, Pulmonary (3)  ·  Alcoholism (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  HIV Seropositivity (1)  ·  Hepatitis (1)  ·  Infertility, Female (1)  ·  Kidney Failure, Chronic (1)  ·  Latent Infection (1)  ·  Patient Compliance (1)  ·  Renal Insufficiency (1)

Sponsors

Instituto Nacional de Salud Publica, Mexico (4)  ·  Beijing Chest Hospital (3)  ·  Aswan University Hospital (2)  ·  National Taiwan University Hospital (2)  ·  Sociedad Andaluza de Enfermedades Infecciosas (2)  ·  ANRS, Emerging Infectious Diseases (1)  ·  Aarhus University Hospital (1)  ·  Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1)  ·  Centers for Disease Control and Prevention (1)  ·  Herlev and Gentofte Hospital (1)  ·  Hospital Universitari de Bellvitge (1)  ·  Hospital Virgen de la Luz (1)  ·  Johns Hopkins University (1)  ·  Makerere University (1)  ·  Miguel Santín (1)

Countries

Uganda (5)  ·  China (4)  ·  Spain (4)  ·  India (3)  ·  Mexico (3)  ·  South Africa (3)  ·  Taiwan (3)  ·  Botswana (2)  ·  Brazil (2)  ·  Denmark (2)  ·  Egypt (2)  ·  Haiti (2)  ·  Zimbabwe (2)  ·  Cambodia (1)  ·  Côte d’Ivoire (1)

Top investigators

Antonio Rivero, MD PhD (2)  ·  Felipes Diez, MD (2)  ·  Fernando Lozano, MD PhD (2)  ·  Jose Carlos Escribano, MD (2)  ·  Juan Jose Hernandez, MD (2)  ·  Juan Pasquau, MD (2)  ·  Manuel Marquez, MD (2)  ·  Rafael Castillo, MD (2)  ·  Alfredo Ponce-de-Leon, MD (1)

Results publications

PMID 25359354, PMID 12809582, PMID 17504682, PMID 21492926, PMID 21541021, PMID 22046230, PMID 23150149, PMID 23317952, PMID 23533318, PMID 25340318, PMID 27025337, PMID 28399802, PMID 28629333, PMID 28928173, PMID 29020191, PMID 29162063, PMID 29514175, PMID 29519716, PMID 30910890, PMID 31577875, PMID 31761933, PMID 32558469, PMID 33146706, PMID 36044285, PMID 36269714, PMID 36883573, PMID 37634517, PMID 38918780, PMID 39350021, PMID 41666121

NIH funding

2009 (1), U01AI068636 (1), U01AI152961 (1)